s6y

MapLight Therapeutics, Inc.

Ticker
MPLT
CIK
1770069
Industry
Pharmaceutical Preparations
Formerly
Alvarado Therapeutics, Inc.

Financials 5

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025

News 13

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 13 news filings

Ownership 100

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 100 ownership filings

Prospectus 19

  1. S-3 Registration statement for specified transactions by certain issuers
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. S-1/A General form of registration statement for all companies including face-amount certificate companies
  4. S-1 General form of registration statement for all companies including face-amount certificate companies
  5. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  8. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  9. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  10. S-1/A General form of registration statement for all companies including face-amount certificate companies

All 19 prospectus filings

Proxies 2

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements

Other 78

  1. EFFECT Notice of Effectiveness
  2. SCHEDULE 13G/A
  3. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  4. SCHEDULE 13G/A
  5. 144 Filing for proposed sale of securities under Rule 144
  6. 144 Filing for proposed sale of securities under Rule 144
  7. 144 Filing for proposed sale of securities under Rule 144
  8. 144 Filing for proposed sale of securities under Rule 144
  9. 144 Filing for proposed sale of securities under Rule 144
  10. 144 Filing for proposed sale of securities under Rule 144

All 78 other filings